FiLeClo is revolutionising the cytostatic drug market with a new salinomycin derivative designed to target cancer cells selectively and eliminate harmful side effects.
EXEQ developed a tailored funding strategy to help FiLeClo secure grants for its research, preclinical, and clinical development phases. Our team worked closely with FiLeClo to structure projects that align with the requirements of selected national funding programs and prepared two successful applications. EXEQ continues to support FiLeClo with ongoing reporting and securing funds for future development initiatives.
Scope:
- Funding Roadmap
- Grant Writing & Accounting
Supporting FiLeClo's Vision for Revolutionary Cancer Treatment
FiLeClo approached EXEQ with an innovative concept for a cytostatic drug candidate derived from a natural compound. To bring this idea to life, FiLeClo needed a comprehensive strategy, ensuring a strong foundation for successful applications to relevant funding programs. Key elements of the strategy included a detailed R&D roadmap with clear timelines, an in-depth analysis of the market size and potential, and a robust clinical trial plan. In addition, a strategic approach to IP protection and regulatory compliance was essential to support future market entry.
Empowering FiLeClo's Breakthroughs in Drug Development
FiLeClo, a leader in organic chemistry, sought support in advancing their complex drug development project. EXEQ provided expert guidance to secure funding for FiLeClo’s research and preclinical stages. Building on this success, we also assisted in obtaining a grant to develop and implement their clinical trial plan. Today, EXEQ continues to support FiLeClo with comprehensive grant management services, including procurement and cost accounting. Additionally, we are collaborating with FiLeClo on innovative ideas aimed at addressing new medical challenges.
Securing €7.6M to Propel FiLeClo’s Drug Development Journey
Poland-based FiLeClo has successfully transformed an early-stage lab concept into a drug candidate ready for clinical trials. EXEQ has played a key role in securing a sustainable long-term funding path for this groundbreaking invention. We developed a comprehensive funding strategy and supported FileClo in acquiring €4.7M for preclinical studies in 2020 and €2.9M for clinical development in 2023. To date, EXEQ has guided FiLeClo through research projects totaling €7.6M. We continue to support FiLeClo in advancing the mature stages of drug development and identifying future goals.
